Community-based screening for Down's Syndrome in the first trimester using ultrasound and maternal serum biochemistry

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 112, Issue 11, 2005, Pages 1561-1564

  Hadlow, Narelle C ^a   Hewitt, Beverley G ^b   Dickinson, Jan E ^c   Jacoby, Peter ^d   Bower, Carol ^d  

^a WESTERN DIAGNOSTIC PATHOLOGY   (Australia)

^b Park Ultrasound   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ACCREDITATION; ADULT; ARTICLE; AUSTRALIA; BLOOD CHEMISTRY; COMMUNITY PROGRAM; COMPUTER PROGRAM; DOWN SYNDROME; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MATERNAL BLOOD; NUCHAL TRANSLUCENCY MEASUREMENT; OUTCOME ASSESSMENT; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; RADIOLOGICAL TECHNOLOGIST; RISK ASSESSMENT; SONOLOGIST; TRISOMY 21; ULTRASOUND; BLOOD; CLINICAL TRIAL; COLPOSCOPY; COMMUNITY CARE; ECHOGRAPHY; KARYOTYPING; LABORATORY DIAGNOSIS; METHODOLOGY; MULTICENTER STUDY; PREGNANCY; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY; VAGINA SMEAR;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; COLPOSCOPY; COMMUNITY HEALTH SERVICES; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; KARYOTYPING; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VAGINAL SMEARS;

EID: 33644631718     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2005.00722.x     Document Type: Article

References (7)

1. Mulvey S, Wallace EM. Women's knowledge of and attitudes to first and second trimester screening for Down syndrome. BJOG 2000 107 : 1302 1305.
2. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for Trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β hCG and PAPP-A. Ultrasound Obstet Gynecol 1999 13 : 231 237.
3. Spencer K, Spencer CE, Power M, Dawson C, Nicholaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003 110 : 281 286.
4. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's Syndrome based on tests performed during the first and second trimesters. NEJM 1999 341 : 461 467.
5. Cuckle HS. Growing complexity in the choice of Down's Syndrome screening policy. Ultrasound Obstet Gynecol 2002 19 : 323 326.
6. Bower C, Ryan A, Rudy E, Cosgrove P. Annual report of the Western Australian birth defects registry: King Edward Memorial Hospital, 2002.
7. Spencer K, Crossley JA, Aitken DA, Nix ABJ, Dunstan FDJ, Williams K. The effect of temporal variation in biochemical markers of Trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down syndrome. Ann Clin Biochem 2003 40 (3 219 231.